News and Updates
Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020
NATO Chief Scientist Grants Programme
Published on | 2 months ago
Programmes Security Digital, Industry & Space Cybersecurity Defence NATO-EDAApplications are open until 15 November 2024
About the Programme
The NATO Chief Scientist Grants Programme is dedicated to fostering excellence in science and technology research. It is committed to supporting groundbreaking projects that contribute to global security and scientific advancement. The programme particularly encourages applications from qualified women in STEM fields, recognizing the vital importance of diverse perspectives in addressing complex security challenges.
In 2025, the programme will award 500,000 Euros in total to fund the following types of activities:
- S&T Studies on Emerging Topics
One of the primary purposes of the Office of the Chief Scientist (OCS) is to disseminate timely, clear, and up-to-date scientific advice and technical information related to defence activities to NATO Allies. Every year, the OCS publishes a list of S&T themes and invites applicants to submit research proposals. If selected, applicants must produce a research report on that topic. - S&T Awareness Initiatives
In a world where NATO S&T efforts continue to make great headways in improving the security of its Allies, the STO aims for an increased awareness of its S&T prowess and an inclusive and diverse reinforcement of its community of experts. Every year, the OCS publishes a list of S&T themes and invites applicants to submit S&T Awareness Initiatives on those topics. In particular, two types of activities are envisaged:
- Events and projects established to raise awareness of STO’s efforts and mission
- Initiatives that widen the STO scientific knowledge base, attracting under-represented talent from the STEM ecosystem to deliver cutting-edge S&T
*Please note that grants may vary in size, but typically they will range between 25,000 and 100,000 Euros.
More information on the website of NATO Chief Scientist Grants
Related News
|
2024-12-10
|
5 days ago |
STARHAUS Open Calls on Open Innovation and Creativity |
|
2024-12-09
|
6 days ago |
Innovation Prize Open Call - GOBEYOND |
|
2024-12-09
|
6 days ago |
Looking for Virtual World - Metaverse - Extended Reality Initiatives |
|
2024-12-05
|
1 week ago |
Commission launches Industry-Academia Network to bridge cybersecurity skills gap |
|
2024-12-04
|
1 week ago |
The Strategic Technologies for Europe Platform - the STEP funding dashboard with open... |
|
2024-11-15
|
1 month ago |
Commission consultation on AI Act prohibitions and AI system definition |
|
2024-11-15
|
1 month ago |
First draft of General-Purpose Artificial Intelligence Code of Practice |
|
2024-11-08
|
1 month ago |
Update on the 2025 call topics |
myOVERVIEW
-
sign up for personalised information
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Latest News
1502 articles available search in articlesTestimonial
BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
